Clinical trials: ALK-positive Advanced Tumors
Carcinoma, Non-Small-Cell Lung
Cerebrospinal Fluid Immune Microenvironment Mechanism in Anaplastic Lymphoma Kinase Positive Lung Cancer Patients
This is an an interventional study to explore the mechanism of cerebrospinal fluid immune microenvironment in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer with brain metastases…
- Trial name
- NCT06697990
- Testing
- Iruplinalib
- Volunteers
- 12 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in…
- Conditions
- Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma
- Trial name
- NCT02978625
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 36 sites in United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.
This phase I, first-in-human dose-escalation study was conducted to determine the maximum tolerated dose (MTD), recommended phase II dose (RP2D), dose-limiting toxicities (DLTs), pharmacokinetics (PK) profile, and preliminary…
- Trial name
- NCT03130881
- Testing
- PLB1003
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Pearl Biotechnology Limited Liability Company
Non-Small Cell Lung Cancer ALK-positive
A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC
The purpose of this retrospective study is to learn about the real-world effects of the study medicine lorlatinib for the first-line treatment of Chinese adult patients who were diagnosed with ALK-positive a/mNSCLC.
- Trial name
- NCT07556549
- Testing
- Lorlatinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Pfizer
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive…
- Trial name
- NCT02838420
- Testing
- Alectinib, Crizotinib
- Where
- 19 sites in China, South Korea and 1 more
- Volunteers
- 187 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor
PF-07284892 in Participants With Advanced Solid Tumors
The purpose of this first-in-patient, open label study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and…
- Trial name
- NCT04800822
- Testing
- PF-07284892, lorlatinib, binimetinib
- Where
- 11 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Cholangiocarcinoma
A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Primary objective: To investigate the objective response rate in patients with ROS1 or ALK over-expressed locally advanced, or metastatic intrahepatic or hilar cholangiocarcinoma receiving LDK378 Secondary objectives:The…
- Trial name
- NCT02374489
- Testing
- LDK378
- Where
- 2 sites in Taiwan
- Volunteers
- 9 people
- Sponsor
- National Health Research Institutes, Taiwan
Non-Small Cell Lung Cancer, ALK-positive
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of SAF-189s versus crizotinib treatment in participants with treatment-naive ALK-positive advanced NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, ALK-positive, SAF-189s
- Trial name
- NCT06569420
- Testing
- Drug: Foritinib Succinate, Drug: Crizotinib
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non Small Cell Lung Cancer Metastatic
Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer
Crizotinib is a first-generation ALK tyrosine kinase inhibitor (ITK-ALK). It is the standard first-line treatment for patients with advanced NSCLC with ALK gene rearrangement.
- Trial name
- ORAKLE (NCT04111705)
- Testing
- Lorlatinib
- Where
- 32 sites in France
- Volunteers
- 23 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Non Small Cell Lung Cancer
AUY922 for Advanced ALK-positive NSCLC
This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer.
- Trial name
- NCT01752400
- Testing
- AUY922
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Massachusetts General Hospital
Non-Small-Cell Lung, ALK-positive Advanced NSCLC
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
The main purpose of the study is to learn how the lung cancer medicines work. The study also looks into treatment sequence of these medicines.
- Conditions
- Non-Small-Cell Lung, ALK-positive Advanced NSCLC, ALK-positive Non-small-cell Lung Cancer, ALK-positive NSCLC
- Trial name
- NCT07567352
- Testing
- lorlatinib
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Pfizer
Non-Small Cell Lung Cancer (NSCLC)
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
This research study is evaluating two drugs, alectinib and bevacizumab, as possible treatments for Advanced Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02521051
- Testing
- Alectinib, Bevacizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
Carcinoma, Non-Small-Cell Lung
A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China
A Phase 2, multi center, open label, dual cohort study to evaluate the efficacy and safety of lorlatinib (PF 06463922) monotherapy in ALK inhibitor treated locally advanced or metastatic ALK positive non small cell lung cancer…
- Trial name
- NCT03909971
- Testing
- Lorlatinib
- Where
- 21 sites in China
- Volunteers
- 109 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer
To explore the DLT of ZG0418 for Patients with Advanced ALK+ or ROS1+ NSCLC And Previously Treated with Chemotherapy or Crizotinib, and to determine the MTD or the R2PD.
- Trial name
- NSCLC (NCT03607188)
- Testing
- Alkotinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Non Small Cell Lung Cancer
A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 2 study of subjects with ALK positive, advanced NSCLC who have failed up to 3 prior therapies. The study will take place globally at multiple study centers.
- Trial name
- CHIARA (NCT01562015)
- Testing
- Ganetespib
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Synta Pharmaceuticals Corp.
Lung Neoplasms
Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC
This study is a phase II single-arm clinical study.The purpose of this study was to evaluate the efficacy and safety of carrelizumab combined with apatinib mesylate and standard chemotherapy (pemetrexed plus carboplatin) in…
- Trial name
- NCT04425135
- Testing
- Camrelizumab, Apatinib, Pemetrixed
- Volunteers
- 59 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
ALK Positive Non-small Cell Lung Cancer
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
This phase II study is aim to investigate the efficacy, resistance mechanism, safety profile of first-line lorlatinib in China advanced ALK+ non-small cell lung cancer (NSCLC).
- Trial name
- NCT06092086
- Testing
- Loratinib
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Guangdong Association of Clinical Trials
Advanced Malignant Neoplasm, ALK Fusion Protein Expression
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
This phase II trial studies how well brigatinib works in treating patients with ALK and ROS1 gene alterations and solid cancers that have spread to nearby tissue and lymph nodes or other places in the body.
- Conditions
- Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation
- Trial name
- NCT03868423
- Testing
- Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Sponsor
- Sameek Roychowdhury
Neoadjuvant Non-Small Cell Lung Cancer
Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma
The project is a Phase III, randomized, open-label, multicenter study in which approximately 36 patients with unresectable Stage III ALK positive Lung Adenocarcinoma will be randomized 1:1 to receive lorlatinib or…
- Trial name
- NCT06858410
- Testing
- lorlatinib, concurrent/sequential platinum-based chemoradiotherapy
- Volunteers
- 36 people
- Sponsor
- Guangdong Association of Clinical Trials
ALK, NSCLC
The Incidence and Risk Factors of Central Nervous System Adverse Events of Lorlatinib in Patients with ALK-positive Advanced Non-small Cell Lung Cancer: a Real-world Study
The goal of this study is to investigate the incidence and risk factors of central nervous system adverse events of Lorlatinib in patients with ALK-positive advanced non-small cell lung cancer.
- Trial name
- NCT06652555
- Testing
- Group 1
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China